Amity Island
Well-Known Member
- Relationship to Diabetes
- Type 1
Minneapolis-based Endogenex said its endoscopic system uses nonthermal energy to treat inflamed and dysfunctional tissue associated with type 2 diabetic duodenopathy. (ReCET stands for Re-Cellularization via Electroporation Therapy.)
The device developer — founded in partnership with Mayo Clinic — is scheduled to present the findings from its Regent-1 Australia study at Digestive Disease Week (DDW) 2025 in San Diego.
The novel outpatient procedure “regenerates healthy cells in the mucosal and sub-mucosal layers of the duodenum — the top part of the small intestine, where metabolic coordination occurs,” the company said in a statement shared with MassDevice ahead of the presentation.
www.massdevice.com
The device developer — founded in partnership with Mayo Clinic — is scheduled to present the findings from its Regent-1 Australia study at Digestive Disease Week (DDW) 2025 in San Diego.
The novel outpatient procedure “regenerates healthy cells in the mucosal and sub-mucosal layers of the duodenum — the top part of the small intestine, where metabolic coordination occurs,” the company said in a statement shared with MassDevice ahead of the presentation.
Endogenex says ReCET system study shows promise for type 2 diabetes patients
Endogenex said the study "demonstrates substantial and durable reduction in insulin resistance and improvement in beta cell function."
www.massdevice.com